Skip to content
City PM
  • Germany
  • France
  • Europe
  • Markets
  • Business
  • Opinion
  • Germany
  • France
  • Europe
  • Markets
  • Business
  • Opinion
Tuesday 12 May 2026 2:07 pm  |  Updated:  Tuesday 12 May 2026 2:08 pm

Medisca and dsm–firmenich Partner to Expand Access to Pharmaceutical-Grade Vitamin APIs for U.S. Compounding Market

By: Business Wire

Add as a preferred source on Google

Medisca, a global leader in personalized pharmaceutical medicine, has entered into a strategic partnership with dsm–firmenich, a leading ingredient manufacturer serving regulated pharmaceutical markets worldwide.

Through this partnership, Medisca will make a portfolio of pharmaceutical-grade vitamin active pharmaceutical ingredients (APIs) available to U.S. compounding professionals, expanding access to ingredients manufactured within European cGMP environments and supported by established quality systems and documentation standards.

Strengthening the foundation of compounding

As compounding continues to support increasingly complex and regulated care settings, expectations around ingredient sourcing, consistency, and documentation continue to rise. Pharmacies and 503B outsourcing facilities are seeking partners that enable them to operate with confidence at scale.

This partnership reflects a long-term commitment to expanding access to high-quality ingredient solutions while preserving the workflows, relationships, and operational models customers rely on today.

“We are grateful to partner with dsm–firmenich, a global organization recognized for its manufacturing standards and commitment to quality,” said Peng Li, Vice President, Strategic Partnerships at Medisca. “Ingredient sourcing is foundational to trust and long-term success in compounding. By bringing dsm–firmenich pharmaceutical-grade API portfolio into the Medisca ecosystem, we are expanding what our customers can rely on today and supporting how the industry continues to evolve.”

The partnership introduces pharmaceutical-grade vitamin APIs through an established commercial and technical model designed to support regulated use and long-term continuity across compounding practice.

“Partnering with Medisca is a meaningful step in expanding access to high-quality, pharmaceutical-grade vitamin APIs for the U.S. compounding market. By combining our global manufacturing expertise and commitment to cGMP standards with Medisca’s deep understanding of compounding professionals, we are strengthening supply reliability and enabling pharmacies and 503B outsourcing facilities to operate with greater confidence, consistency, and quality in patient care.” ~Jennifer McManus, Senior Sales Director, dsm-firmenich

The dsm–firmenich vitamin API portfolio is available through Medisca in the United States, with additional products expected to be introduced over time. Customers can contact their Medisca sales representative for ordering information, pricing, and lead times.

About dsm–firmenich

As innovators in nutrition, health, and beauty, dsm–firmenich reinvents, manufactures, and combines vital nutrients, flavors, and fragrances for the world’s growing population to thrive. With its comprehensive range of solutions, natural and renewable ingredients, and renowned science and technology capabilities, the company creates what is essential for life, desirable for consumers, and more sustainable for people and the planet. dsm–firmenich is a Swiss company with dual headquarters in Kaiseraugst, Switzerland and Maastricht, Netherlands, listed on Euronext Amsterdam, with operations in almost 60 countries and revenues of more than €12 billion. With a diverse, worldwide team of nearly 30,000 employees, dsm–firmenich brings progress to life every day, everywhere, for billions of people. www.dsm-firmenich.com

About Medisca

Founded in 1989, Medisca is a leader in personalized medicine and pharmaceutical supply chain solutions, with a vast portfolio of over 2,000 products complemented by a library of 10,000+ proprietary and customized medication formulas, expertise and services in pharmaceutical compounding, continuing healthcare education, and analytical testing. Providing finely-tuned solutions to diverse wellness sectors in numerous markets globally, Medisca is bridging the gaps in healthcare and empowering personalized wellness for all. For more information, visit www.medisca.com and follow us on LinkedIn, Facebook, and YouTube.

Medisca and dsm–firmenich executives shaking hands, symbolizing partnership for U.S. compounding market vitamin APIs

View source version on businesswire.com: https://www.businesswire.com/news/home/20260512963697/en/

Contact

Medisca Communications
[email protected]
1-800-665-6334

TweetText

“By bringing dsm–firmenich pharmaceutical-grade API portfolio into the Medisca ecosystem, we are expanding what our customers can rely on today and supporting how the industry continues to evolve.” Peng Li, Vice President, Strategic Partnerships at Medisca

Company Logo
Company Logo
Read more

Medisca Enters Its Next Chapter Under Founder Antonio Dos Santos

Share this article

  • Facebook
  • X
  • LinkedIn
  • WhatsApp
  • Email

Similarly tagged content:

Sections

  • Businesswire

Categories

  • Contract/Agreement
  • Product/Service

Trending Articles

  • Burnham tax plans spark investor rush to bank capital gains

  • Brewdog chief executive quits after only one year

  • Nothing fails to file accounts months after dissolution threat

  • UK ‘no longer a serious place’ says Hedge fund boss after losing £200m tax battle

  • Cruyff turn: Starmer allows pubs to stay open for England World Cup game

More from City PM

  • Medisca Enters Its Next Chapter Under Founder Antonio Dos Santos

    Business Wire
  • ICON selects Microsoft as a preferred technology partner to power AI-enabled clinical development

    Business Wire
  • LSE draws up ‘worst case scenario’ US listing flight risk

    Markets
    London Stock Exchange building exterior with financial district skyline, symbolizing global market activity and economic t...
  • Tate & Lyle confirms £2.7bn takeover by US rival

    Markets
    Tate & Lyle headquarters exterior showcasing modern architecture and company signage on a bustling city street
  • Araris Biotech AG and Taiho Oncology Announce Dosing of First Patient in Phase 1 Trial of ARC-02, a Novel ADC for the Treatment of Non-Hodgkin Lymphoma

    Business Wire
  • GSK says AI is reshaping drug pipeline as Nuvalent deal hits shares

    Tech
    GSK said total sales fell by two per cent in the third quarter
  • West Ham sponsor Boyle Sports ‘extremely concerned’ by David Sullivan allegations

    Sport Business
    Getty Images logo on a smartphone screen with a blurred background, representing media and photography business industry.
  • Blackstone Raises its Largest Asia Private Equity Fund at $13.1 Billion

    Business Wire

City PM — European politics, business and analysis.

Europe

  • Germany
  • France
  • Europe
  • UK & Ireland

Topics

  • Business
  • Markets
  • AI
  • Technology
  • Opinion
  • Energy

More

  • Politics
  • Economics
  • Fintech
  • Legal
  • Sport
  • Life

Company

  • About City PM
  • Editorial Policy
  • Corrections
  • Contact
  • Terms of Use
  • Privacy Policy
  • Cookie Policy
© 2026 City PM · Published by CityPM Media, Bahnhofstrasse 65, 8001 Zürich, Switzerland
About · Editorial Policy · Corrections · Contact · Privacy